All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Takeda Pharmaceutical Co. Ltd. and JCR Pharmaceuticals Co. Ltd. have negotiated a geographically-focused licensing deal to develop and commercialize JR-141 (pabinafusp alfa), a potential therapy for mucopolysaccharidosis type II, also known as Hunter syndrome.
